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Human papillomavirus (HPV) type 16 E6 is a viral oncoprotein essential for host cell transformation.
Due to its role in HPV-induced cancers of the genital, head and neck epithelia, reliable protein-level
determination of E6 expression would be an invaluable diagnostic tool. Immunocytochemical detection
and subcellular localization of HPV16 E6 has been demonstrated with varying success and a
comprehensive review of techniques is lacking. To address these issues, we used established
monoclonal antibodies and optimized a standard immunocytochemical method for E6 protein
detection inside the HPV16 positive cell lines, SiHa and CaSki. E6 oncoprotein was detected primarily
in the nucleus. We also reﬁned quantitative analysis with a software to objectively differentiate
between HPV16 positive and negative cells. Our analysis was also able to differentiate expression
differences between SiHa and CaSki on par with RT-qPCR . Thus, we provide a long-needed, robust
protocol for antibody-mediated detection of the HPV16 E6 oncoprotein inside cultured cells.
& 2012 Elsevier Inc. All rights reserved.Introduction
For over two decades, the 18 kDa human papillomavirus (HPV)
type 16 E6 protein has been implicated in phenotype transforma-
tion of cervical carcinoma-derived cell lines. Unlike other HPV16
proteins, which are differentially expressed throughout the viral
life cycle and in the transformed phenotype of the host, E6 is
expressed in both pre-malignant and malignant tissues. These
criteria make E6 an ideal biomarker with diagnostic potential
(Androphy et al., 1987).
Most useful diagnostic tests require the development of anti-
bodies to a key antigen. In the mid-80s, polyclonal HPV18 (second
in prevalence to HPV16) E6 antibodies were generated and used
for immunoblotting of HeLa cells (Matlashewski et al., 1986),
providing the proof-of-concept necessary for the development of
polyclonal antibodies for HPV16 E6. Such antibodies raised in
rabbits against a bacterial HPV16 E6 fusion protein were used for
E6 immunoprecipitation (Androphy et al., 1987). In reﬁning the
process, the hunt for monoclonal antibodies (mAb) against E6
began. Interestingly, one of the ﬁrst HPV18 E6 monoclonalll rights reserved.
al Research Institute, Probe
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on),antibodies, mAb C1P5, cross-reacted with HPV16 E6 in an immu-
noblot of SiHa cells (which contain three HPV16 copies per cell)
(Yee et al., 1985; Baker et al., 1987; Banks et al., 1987). The
epitope recognized by mAb C1P5 represents a region of immu-
nological conservation between HPV16 and HPV18.
Following development of good mAbs to E6, in situ detection of
the E6 protein was the logical next step. Nuclear and membrane
localization for HPV18 E6, with mAb C1P5, was performed using
insect cells (Grossman et al., 1989) and a recombinant baculovirus
expression system that produced HPV proteins with similar
biological properties to native proteins (Park et al., 1993). Further
studies involving a mAb against the HPV16 E6 open reading
frame, but with the precise epitope unknown, showed cytoplas-
mic staining via immunoﬂuorescence (Kim et al., 1994). A mAb
against the 23 amino acid, C-terminal polypeptide of the HPV18
E6 open reading frame was also used to demonstrate nuclear
localization for HPV16 and 18 (Scheffner et al., 1990). Due to the
lack of a reliable detection method, such inconclusive results
were typical of HPV E6 localization studies in the 1990s.
After these early studies, a need was clearly identiﬁed for
generating and characterizing highly reactive and speciﬁc mono-
clonal antibodies to study HPV16 E6 functionality in situ (Wlazlo
et al., 2001). Previous HPV16 E6 localization studies within
human carcinoma cells had produced contradictory results, likely
due to low endogenous E6 protein levels and poor reactivity of
the polyclonal antisera used. In the early 2000s, new mAbs
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determine the precise intracellular localization of E6 in trans-
formed cells and whether the cellular distribution of E6 correlated
with p53-independant functions (Masson et al., 2003). The
purpose was to identify regions of E6 that could be targeted for
functional inhibition: they narrowed their search to a region of 10
residues at the N-terminus of HPV16 E6. In CaSki cells (which
contain about 600 copies per cell of integrated HPV16 and some
HPV18 sequences), they found strong inhibition of p53 proteo-
lysis using these antibodies, speciﬁcally mAb 6F4 (Giovane et al.,
1999). The 4C6 antibody was produced similarly, yielding speci-
ﬁcity to the N-terminus region of HPV16 E6. Immunoblotting
with antibodies 1F4, 1F1, and 6F4 yielded positive results and
indirect immunoﬂuorescence microscopy showed nuclear locali-
zation in transfected cells (Choulier et al., 2002). However, this
group was unable to conﬁdently detect endogenous E6 protein in
CaSki and SiHa, resorting to immunogold staining with electron
microscopy (Masson et al., 2003).
More recently, this group generated monoclonal antibodies
against the second zinc-binding domain of HPV16 E6 (16ZD2) and
used them with the previous 6F4 mAb (N-terminus speciﬁc) to
test their inhibition against E6 with E6AP and degradation of p53
(Lagrange et al., 2005). The three new antibodies made were 1F5,
3B8, and 3F8; these were validated using western blots and
immunoﬂuorescence of transfected cells and CaSki. Finally, they
used delivery of 4C6, 6F4, and 3F8 with small interfering RNA to
SiHa and CaSki to suppress growth by preventing p53 degradation
(Courteˆte et al., 2007). However, in our hands none of the
aforementioned methods yielded reproducible staining.
Overall, a lack of effective, commercially available mAbs for
HPV16 E6 has beleaguered researchers. The purpose of the
current study was to evaluate antibody-mediated detection of
the HPV16 E6 oncoprotein for subcellular localization and expres-
sion analysis. We used the 4C6 Strasbourg clone, based on
preliminary results suggesting it was the best primary antibody
candidate, to establish an optimized technique for colorimetric
immunocytochemistry that could reliably localize E6 oncoprotein
in situ. We then established a quantitative analysis protocol for
determining protein-level HPV16 E6 expression.Results
HPV16 E6 oncoprotein was reliably detected in the nuclei of
established cervical carcinoma cell lines via immunocytochemistry
Accurate and reproducible detection of the HPV16 E6 onco-
protein in situ is useful as a marker for HPV16 presence and
expression of its functional oncoproteins. Speciﬁcally, detection of
E6 provides evidence of protein-level expression and localization
within a cell. Studies which aim to modulate E6 expression and
function require reliable detection of their target to validate the
functional relationship of any experimental response. Typically,
preliminary studies are performed using monolayer cell culture as
a basic biological model. Immunocytochemistry is a commonly
used technique for observing protein expression and localization.
A protocol exists for the detection of HPV16 E6 oncoprotein
(courtesy of Arbor Vita Corporation (Fig. 1)), but it required
optimization in our hands. The UltraVision LP kit (Thermo
Scientiﬁc, Catalog no. TA-125-PH), which was used in the original
protocol, includes a separate antibody enhancer and secondary
HRP-conjugated polymer. This kit is not available in Canada.
Instead, the closest possible substitution, the UltraVision ONE
kit (Thermo Scientiﬁc, Catalog no. TL-060-HLJ) was initially used
as an alternative in the Zehbe laboratory. SiHa and CaSki cell lines,
both of which contain HPV16, were used as positive controls,and C33A, an HPV16 negative carcinoma cell line, was used as a
negative control. Both SiHa and CaSki cells yielded strong positive
staining, but so did C33A cells albeit to a lesser extent (Fig. 2A).
The non-speciﬁc staining in our negative control C33A cells could
be resolved with agitated washing steps (up and down slide dips).
However, this decreased the speciﬁc staining substantially (Fig. 2B)
and could not be compensated by prolonging the incubation time
of primary antibody and subsequent detection steps (data not
shown). Overnight (16 h) antibody incubation at 4 1C did not
appear to have a signiﬁcant improvement to reduce unspeciﬁc
staining and lower antibody concentrations (1–10 mg/mL, com-
pared to 20 mg/mL) decreased the staining intensity for all cells
(data not shown). This prompted us to try the recently launched
Novocastra Bond Polymer Reﬁne Detection kit (Leica Microsys-
tems, Catalog no. DS9800) which offers greater sensitivity than the
UltraVision ONE kit due to a two-step post-primary step with
multifunctional linkers. The new kit enabled positive staining in
SiHa and CaSki cells, predominately localized to the nucleus, but
yielded no staining in C33A cells (Fig. 3A). E6 staining in SiHa and
CaSki was not seen in all cells, and did not appear to have uniform
intensity. SiHa had fewer and less intensely positive cells compared
to CaSki. Omission of the primary antibody gave no staining in any
cells, indicating that positive staining is due to the primary anti-
body (Fig. 3B). Consistent results were observed in two indepen-
dent laboratories (the Arbor Vita and the Zehbe lab), with testing
done by separate individuals, yielding a reﬁned detection protocol
(Fig. 4). Two other Strasbourg clones, 3F8 and 6F4, the latter of
which works well in Western blots (Zehbe et al., 2009), were also
tried with our optimized protocol in the Zehbe lab. However, these
clones yielded non-speciﬁc cytoplasmic staining in HPV positive
and negative cells alike, which was not improved by changing
ﬁxation to paraformaldehyde, methanol or acetone (data not
shown).
Quantitative analysis of immunocytochemistry for unbiased
detection of HPV16 E6 oncoprotein expression
To shed the constraints of subjectivity, as offered by qualita-
tive results, a quantitative analysis protocol was developed using
the CellProﬁler software (Carpenter et al., 2006; Kamentsky et al.,
2011). CellProﬁler allows the complex and automatic analysis of
biological images. The user designs ‘‘pipelines’’ by specifying
individual functions to be performed in sequential order; repro-
ducible and customizable analysis of large image-sets is possible.
For our purposes, images were processed by ﬁrst identifying
individual cells based on DAB and haematoxylin stain followed
by isolating, measuring, and averaging cell DAB intensities
(Fig. 5). This process was performed iteratively for 25 images
each of SiHa, CaSki, and C33A. An objective analysis was thus
employed to determine if there were signiﬁcant differences
between positive and negative controls.
Mean intensities derived from CellProﬁler analysis of
400 images were determined to be non-parametric and were
statistically tested using a Kruskal–Wallis rank sum test (non-
parametric ANOVA equivalent) followed by pairwise Wilcoxon
rank sum post-hoc analysis. CaSki and SiHa both had signiﬁcantly
higher mean intensities than negative control C33A and all no
primary Ab controls (nnnPo0.001, n¼25) (Fig. 6). CaSki had 5.8
fold greater mean intensity than SiHa (nnnPo0.001, n¼25). There
was no signiﬁcant difference between C33A and no primary Ab
control cells.
Since the cervical carcinoma cell line CaSki has approximately
200 times more viral DNA copies than SiHa, transcript and protein-
level fold change was calculated to determine if this magnitude of
difference was also reﬂected throughout transcription and transla-
tion. Relative transcript-level differences, as determined by standard
Fig. 1. Flowchart of original immunocytochemical protocol for detection of HPV16 E6 oncoprotein. The original protocol provided by Arbor Vita Corporation using the
UltraVision LP kit (Thermo Scientiﬁc, Catalog no. TA-125-PH). Cells were stored in ﬁxative at 4 1C. Unless otherwise stated, all subsequent steps were performed at room
temperature.
Fig. 2. Immunocytochemical detection of HPV16 E6 oncoprotein using the original protocol. Micrographs of immunocytochemistry for HPV16 E6 oncoprotein using the
original protocol with (A) mAb 4C6 primary antibody and the UltraVision ONE kit and (B) same procedure, but with agitated washing steps. Distinct brown color, caused by
oxidation of DAB by HRP, represents positive staining. Images are cropped from 400 magniﬁed captures. Linear adjustments to brightness and contrast were applied
consistently for all images.
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Fig. 3. Optimized immunocytochemical detection of HPV16 E6 oncoprotein. Micrographs of immunocytochemistry for HPV16 E6 oncoprotein using the modiﬁed protocol
with (A) mAb 4C6 primary antibody and (B) with no primary antibody. Distinct brown color, caused by oxidation of DAB by HRP, represents positive staining.
Haematoxylin was used as a counterstain. Images are cropped from 400 magniﬁed captures. Linear adjustments to brightness and contrast were applied consistently for
all images.
Fig. 4. Flowchart of modiﬁed immunocytochemical protocol for detection of HPV16 E6 oncoprotein. Our modiﬁed protocol for the detection of HPV16 E6 oncoprotein
using the Novocastra Bond Polymer Reﬁne Detection kit (Leica Microsystems, Catalog no. DS9800). Cells were stored in ﬁxative at 4 1C. Unless otherwise stated, all
subsequent steps were performed at room temperature.
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Fig. 5. CellProﬁler was used to objectively measure DAB intensity from immuno-
cytochemistry images. Using CellProﬁler software, images were converted to
greyscale haematoxylin and DAB. The ‘‘IdentifyPrimaryObjects’’ function was used
to outline individual cells from the background, followed by object assignment.
Mean DAB intensity was measured automatically for each image by calculating
and averaging the greyscale DAB intensity for every object.
Fig. 6. Quantitative analysis demonstrates signiﬁcant signal intensity differences
between CaSki, SiHa, and C33A. Mean intensities (relative units) derived from
CellProﬁler analysis were analyzed using a Kruskal–Wallis rank sum test (non-
parametric ANOVA equivalent) followed by pairwise Wilcoxon rank sum post-hoc
tests. CaSki and SiHa both had signiﬁcantly higher mean intensity than negative control
C33A and all no primary Ab controls (nnnPo0.001, n¼25). CaSki had 5.8 fold greater
mean intensity than SiHa (nnnPo0.001, n¼25). There was no signiﬁcant difference
between C33A and no primary Ab control cells. Means are presented as mean 7SEM.
Fig. 7. DNA, mRNA, and protein-level fold change between CaSki (high-copy) and
SiHa (low-copy) cervical carcinoma cell lines. Caski had 200 fold greater viral
copies, 5.7 fold greater E6 transcript expression (*Po0.05, n¼3), and 5.8 fold
greater E6 protein expression (**Po0.01, n¼25) compared to SiHa. Welch’s two-
sample t-test for unequal variances was used for comparing fold change data. SiHa
has fold change of 1 for baseline. Means are presented as mean 7SEM.
Fig. 8. Quantitative analysis can demonstrate signiﬁcant signal intensity differ-
ences between HPV16 E6 positive and negative cells with high background. Mean
intensities (relative units) derived from CellProﬁler analysis were determined to
be parametric and were tested using a one-way ﬁxed effects ANOVA followed by
Tukey’s HSD post-hoc analysis. CaSki and SiHa both had signiﬁcantly higher mean
DAB intensity than the negative cells (*Po0.05, n¼5) but were not signiﬁcantly
different from each other. There was no signiﬁcant difference between negative
cells. Means are presented as mean 7SEM.
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Welch’s two-sample t-test for unequal variance was used for
statistical comparison. CaSki had 5.7 fold greater E6 mRNAexpression than SiHa (nPo0.05, n¼3), approximately equal to
protein expression fold change of 5.8 (nnPo0.01, n¼25), but
much lower than the 200 fold change in viral copy number.
To further demonstrate the utility of this quantitative analy-
sis, mean intensities were also determined from staining with
high background in positive and negative cell lines (as seen in
Fig. 2). Mean intensities derived from CellProﬁler analysis of
400 mAb 4C6 images were determined to be parametric and
were statistically tested using a one-way ﬁxed effects ANOVA,
followed by Tukey’s HSD post-hoc analysis. CaSki and SiHa both
had signiﬁcantly higher mean DAB intensity than C33A cells
(nPo0.05, n¼5), but were not signiﬁcantly different from each
other (Fig. 8).Discussion
In this paper, we present the results of rigorous testing,
resulting in a protocol for reliable detection of the HPV16 E6
oncoprotein via immunocytochemistry followed by a reﬁned
quantitative analysis. Speciﬁcally, using this optimized detection
method we have demonstrated that E6 oncoprotein is mainly
located in the nucleus and consistent with relative mRNA
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detection threshold for samples of unknown E6 status; this would
be of great importance for diagnostics and research purposes alike.
The complexity in detecting the in situ HPV16 E6 protein is due
to a combination of several factors: antibody sensitivity, antigen
availability, and technique-speciﬁc handling. Prior to our study,
antibody sensitivity and speciﬁcity had been a necessary focus of
research. Although we now have effective anti-HPV16 E6 anti-
bodies, such as mAb 4C6, we still must be concerned about the
availability of E6 protein as an antigen (Masson et al., 2003;
Lagrange et al., 2005). HPV16 E6 is quite promiscuous; the two
zinc-binding domains and C-terminal PDZ-binding domain allow
interaction with a variety of cellular proteins, with many that act
in the nucleus at a transcriptional level (Mantovani and Banks,
2001; Kumar et al., 2002). Our results conﬁrm a primarily nuclear
localization of E6 oncoprotein, as suspected due to its binding
activities, and as previously evidenced by electron microscopy
coupled with immunogold staining (Masson et al., 2003). An
interesting ﬁnding is the lack of E6-positive staining in some
cells. This staining pattern could be explained by differential
expression of E6 in unsynchronized cell cultures which is
paralleled by the fact that p53 is sporadically present (Jackson
et al., unpublished data). There is also a potential with higher
passage and conﬂuent cells to have E6 expression drop off,
possibly due to an accumultation of mutations making E6 super-
ﬂuous while activating different pathways to allow continued
proliferation.
Experimenter-speciﬁc handling and bias is an issue with most
immunocytochemical techniques. To limit subjectivity, our quan-
titative analysis allows an objective method of assaying samples.
One potential problem is inter-experimental staining variability
associated with imaging properties (brightness, DAB staining,
microscope and image capture parameters, etc.). Despite this
potential drawback, automated analysis is easily implemented
in CellProﬁler, while relative staining intensities between positive
and negative biological samples should remain distinguishable
(Carpenter et al., 2006; Kamentsky et al., 2011). The consistency
of relative E6 mRNA and protein levels between CaSki and SiHa is
another supportive ﬁnding, lending credence to the reliability of
our technique. Although transcript-level differences in general do
not necessary equal protein differences in situ, this consistency is
interesting in light of the much higher difference in viral copy
number between these two cell lines. Although a recent study has
aimed to clarify these differences (Roberts et al., 2008), it appears
that the amount of viral DNA does not correspond linearly to E6
transcription and translation. For HPV16 researchers, subcellular
co-localization and quantiﬁcation with functionally important
molecules (such as p53) can be easily implemented. To enhance
subcellular features, cells may be prepared and stained directly on
chamber slides rather than by gravitation. Finally, immunocyto-
chemistry coupled with quantitative analyses may also be applied
to clinical samples to offer an objective and potentially automated
test.
The HPV16 E6 oncoprotein remains an important potential
diagnostic biomarker for invasive cervical cancer and pre-
cancerous lesions (Sellors et al., 2011). The systematic study
presented here serves as a foundation for in situ antibody-
mediated detection of the HPV16 E6 oncoprotein. We conﬁrmed
nuclear localization and relative expression levels of E6 in cervical
carcinoma cells CaSki and SiHa. Most importantly, we have
demonstrated an objective quantitative method for in situ
protein-level detection of E6. The optimization of standard
immunological techniques for HPV16 E6 detection will prove
useful in a variety of scenarios, both research and clinical. Our
protocol can be implemented in clinical labs, given the routine
use of compatible and automated detection systems. Additionally,software could be developed that enables objective and automatic
quantiﬁcation of HPV16 E6 protein in clinical samples.Materials and methods
Cell culture
All mammalian cell cultures were maintained in a 5% CO2,
37 1C humidiﬁed incubator, with nutrient growth media replaced
every second day and routine veriﬁcation of Mycoplasma contam-
ination, as indicated by DAPI-based testing. Both cervical carci-
noma cell lines SiHa (ATCC HTB-35) (Friedl et al., 1970) and CaSki
(ATCC CRL-1550) (Pattillo et al., 1977) were used as HPV16 E6
positive controls. CaSki was passaged at lower conﬂuence (60% vs.
70% conﬂuence for all other cells) due to suspected loss of E6
expression at high densities. C33A (ATCC HTB-31), a HPV negative
cervical carcinoma cell line, was used as a negative carcinoma
control (Auersperg, 1964). Cervical carcinoma cell lines SiHa,
CaSki, and C33A were all maintained in DMEM (Sigma-Aldrich,
Catalog no. D5796) supplemented with 10% FBS (Sigma-Aldrich,
Catalog no. F6178) and 1% antibiotic/antimycotic (Invitrogen,
Catalog no. 15240-062).
Antibodies
Clones 4C6, 6F4 and 3F8 (Masson et al., 2003; Lagrange et al.,
2005) were used as primary monoclonal mouse anti-HPV16
E6 antibodies. Epitopes for 4C6 and 6F4 are known to reside in
the N-terminus region of the E6 protein and clone 3F8 has
epitopes in the C-terminus region of the E6 protein. All three
mAbs were provided by Arbor Vita through communication with
Dr. Johannes Schweizer. Antibody stocks were stored at 80 1C
while short-term working stocks were stored at 4 1C. For immu-
nocytochemistry, mAb mouse anti-a-tubulin (Sigma, Catalog no.
T6074-200UL) diluted 1:500 (4 mg/mL) and mAb rabbit anti-
human p53 (DAKO, Catalog no. M3629) at 1:100 (0.24 mg/mL)
were used as system controls.
Preparation of microscope slides
Cells were trypsinized, counted, washed with PBS by centrifuga-
tion, and resuspended in PBS. Cell suspensions were ﬁxed 1:20 (v/v)
in a buffered methanol-based ThinPrep Non-Gyn PreservCyt solu-
tion (Hologic, Catalog no. 234004). Fixed suspensions were stored at
4 1C for up to 2 months. For slide preparation, ﬁxed cells were
centrifuged and resuspended in PBS at a concentration of 1.0–
1.5106 cells/mL. Cytospin 3 Cell Preparation System (Thermo
Shandon) was used to prepare microscope slides via gravitation.
100 mL (1.0–1.5105 cells) was added to each cytofunnel chamber.
Slides were centrifuged at 1000 RPM for 5 min, air dried for 5 min,
and immediately used for immunological detection.
Immunocytochemistry
Several variations of the following procedure were attempted
and reported within the results; what follows is an optimized
protocol. Hydrophobic barriers were drawn around ﬁxed cell zones
using a wax pencil or Dako pen (DAKO, Catalog no. S2002). Cells
were then permeabilized for 5 min with 100 mL 0.1% (v/v) Triton X-
100 (Cedarlane Labs, Catalog no. T8655) in Tris buffered saline
(TBS) with 0.05% (w/v) sodium azide at room temperature in an
aluminum foil-covered, humidiﬁed tray. The pH of all buffered TBS
stocks was regularly monitored to be in the range of 7.4–7.5 at
room temperature. All of the following reagent incubations were
performed similarly. Permeabilized slides were placed in a rack
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(TBS-t) (Thermo Scientiﬁc, Catalog no. TA-125-TW) with 10 up-
down slide dips for each wash. Endogenous peroxidase activity was
blocked by applying 3% hydrogen peroxide for 10 min followed by
washing as above. For HPV16 E6 detection, primary mouse mAb
4C6 was applied at 20 mg/mL in 1% bovine serum albumin in TBS
with 0.05% sodium azide for 30 min. As a system control, a-tubulin
and p53 were also detected. Non-speciﬁc secondary antibody
binding was controlled by omitting the primary antibody and
applying just diluent. Slides were washed as before followed by
application of Novocastra Bond Polymer Reﬁne Detection kit post-
primary reagent for 10 min (Leica Microsystems, Catalog no.
DS9800). Slides were washed as before and incubated with the
secondary polymer for 15 min. Colorimetric detection was facili-
tated by application of 3,3’-diaminobenzidine (DABþ) chromogen
(DAKO, Catalog no. K3468). Slides were rinsed and washed 3 times
for 3 min with distilled water. If haematoxylin counterstain was
desired, slides were dipped in Harris haematoxylin and blued
under cold tap water to preferred intensity. Slides were ﬁnally
rinsed with distilled water and cover slips were applied using 1–2
drops of mounting medium (Vector Laboratories, Catalog no.
H-1000). Stained cells were inspected by bright ﬁeld microscopy
(Zeiss Axioskop) and images were digitally captured (QImaging
Retiga 1300 RGB camera). HPV16 E6 positive cells were identiﬁed
by their distinctive dark brown stain while negative cells had no
staining.
Quantitative and statistical analyses of DAB staining intensity
CellProﬁler, an image processing application, was used to calculate
relative intensity of DAB stain in cells (Carpenter et al., 2006;
Kamentsky et al., 2011). The following processing pipeline was used:
‘‘LoadImages’’, ‘‘ColorToGray’’, ‘‘ImageMath’’, ‘‘ImageMath’’, ‘‘Unmix-
Colors’’, ‘‘ImageMath’’, ‘‘Morph’’, ‘‘Smooth’’, ‘‘IdentifyPrimaryObjects’’,
‘‘ExpandOrShrinkObjects’’, ‘‘OverlayOutlines’’, ‘‘SaveImages’’, ‘‘Measur-
eObjectIntensity’’, and ‘‘ExportToSpreadsheet’’. Raw DAB with hae-
matoxylin images at 400 magniﬁcation were ﬁrst loaded. Brown
DAB stain was then isolated by dividing a color image into grayscale
RGB channels using ‘‘ColorToGray’’ and dividing the red channel (with
higher DAB intensity) by the blue channel (lower DAB intensity) using
‘‘ImageMath’’ functions. Cells were identiﬁed by ﬁrst using ‘‘Unmix-
Colors’’ to convert the original color image to grayscale background,
DAB, and haematoxylin components. DAB and haematoxylin images
were added using ‘‘ImageMath’’ to preserve cell details equally. To
allow easier identiﬁcation of clustered cells, pixels were eroded and
smoothed using ‘‘Morph’’ and ‘‘Smooth’’. Individual cells in each
image were identiﬁed by the following parameters of ‘‘IdentifyPri-
maryObjects’’: typical object diameter of 35–150 pixel units with
outliers discarded, Otsu Global background three-class thresholding
method, weighted variance minimized, threshold correction factor of
0.5 with bounds 0.0–1.0, clumped objects distinguished and divided
based on intensity, automatically calculated size of smoothing ﬁlter,
and minimum allowed distance between clumped objects. Objects
were expanded to reclaim eroded area using ‘‘ExpandOrShrinkOb-
jects’’. To verify the accuracy of automated cell identiﬁcation, outlines
were overlaid onto original color images of cells. The intensity of DAB
stain in each cell region was measured in relative units (RU) for each
image using ‘‘MeasureObjectIntensity’’ and exported to a comma
separated value (csv) ﬁle for statistical analysis.
Data was determined to meet parametric assumptions based on
normality, homogeneity of variance, and independence. Normality
was tested using histogram, Q–Q plots, and Shapiro–Wilk ’s test.
Homogeneity of variance was tested using a Bartlett or Levene test.
If parametric assumptions were met, a one-way ﬁxed effects
ANOVA was employed with Tukey’s HSD post-hoc if appropriate.
Non-parametric data was subjected to the Kruskal–Wallis testfollowed by pairwise Wilcoxon rank-sum post-hoc. Signiﬁcance
level (a) was set, a priori, at 0.05. Data are presented as means
7SEM. Statistical analyses were performed using the statistical
programming language R (version 2.15.0; R Development Core
Team, 2008).
Transcript expression by RT-qPCR
RNA was extracted from cell pellets using the Arcturus
PicoPure RNA Isolation kit (Applied Biosystems, Catalog no.
KIT0204), with the optional DNase treatment, then reverse
transcribed to complementary DNA using the High Capacity cDNA
Archive kit (Applied Biosystems, Catalog no. 4322171). Reactions
were made up to 60 mL with the following master mix compo-
nents: 1X RT buffer, 1X primers, 1X dNTPs, multiscribe enzyme,
nuclease-free dH2O, and 30 mL RNA template. No-template con-
trols were run with each reaction. Thermocycler (2720 Thermal
Cycler, Applied Biosystems) parameters were as follows: 10 min
25 1C, 120 min 37 1C, and 5 min 85 1C followed by a 4 1C hold. E6
mRNA transcript expression was analyzed by RT-qPCR with the
Applied Biosystems 7500 Real-Time PCR System. Reactions con-
sisted of 150 ng of cDNA, 45 mL of TaqMans Gene Expression
Master Mix (Applied Biosystems, Catalog no. 4369016), 4.5 mL of
TaqMans Gene Expression Assay hydrolysis probes (Assay ID:
AIAAY0O), and nuclease-free dH2O to make up volume to 90 mL.
Triplicate reaction volumes of 25 mL were loaded into a transpar-
ent 96-well plate and analyzed. Hypoxanthine phosphoribosyl-
transferase 1 (HPRT1) was chosen as a suitable reference gene
based on previous optimization experiments (DeCarlo et al.,
2008). Fold change (relative expression ratio) was calculated by
the Livak method (2DDCt, Livak and Schmittgen, 2001). Statistical
analysis was performed as described in the previous section, but
with a Welch’s two-sample t-test for unequal variances.Acknowledgments
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